These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2347953)

  • 1. European registration: today, tomorrow, and beyond.
    Currie WJ
    J Clin Pharmacol; 1990 May; 30(5):386-9. PubMed ID: 2347953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving horizon of drug registration--Europe and beyond.
    Currie WJ
    Eur J Clin Pharmacol; 1990; 39(5):453-6. PubMed ID: 2076736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1992. Is there the will for there to be a way?
    Currie WJ
    J Clin Pharmacol; 1989 Sep; 29(9):770-4. PubMed ID: 2808743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical regulation in the European Community: barriers to single market integration.
    Orzack LH; Kaitin KI; Lasagna L
    J Health Polit Policy Law; 1992; 17(4):847-68. PubMed ID: 1299692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory aspects of stability testing in Europe.
    Matthews BR
    Drug Dev Ind Pharm; 1999 Jul; 25(7):831-56. PubMed ID: 10459489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulation of medicines post 1992.
    Currie WJ
    Eur J Clin Pharmacol; 1989; 37(5):433-5. PubMed ID: 2598981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Marketing of medicinal products in the European Community. The Mutual Recognition and Decentralised Procedures].
    Bachmann P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):722-30. PubMed ID: 18560780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The single market for pharmaceuticals in the European Union in light of European Court of Justice rulings.
    Kanavos P
    Pharmacoeconomics; 2000 Dec; 18(6):523-32. PubMed ID: 11227392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicinal products in the European Union--between harmonization and divergence.
    Lojko N
    Med Law; 2010 Mar; 29(1):61-76. PubMed ID: 22457998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Revision of the European pharmaceutical legislation].
    Sitbon G
    Ann Pharm Fr; 2004 May; 62(3):201-6. PubMed ID: 15243354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States.
    Qu L; Zou W; Wang Y; Wang M
    Phytomedicine; 2018 Mar; 42():219-225. PubMed ID: 29655689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is parallel trade in medicines compatible with the single European market?
    Senior I
    Pharmacoeconomics; 1992; 1(Suppl 1):70-6. PubMed ID: 10172047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Harmonisation of the Marketing Authorisation Application dossier: perspectives due to harmonised requirements. Assessing Rules and the Common Technical Document].
    Menges K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):748-56. PubMed ID: 18584104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory Consequences of "Brexit" for the Development of Medicinal Products.
    Jackson EL; Feldschreiber P; Breckenridge A
    Clin Pharmacol Ther; 2017 Aug; 102(2):183-184. PubMed ID: 28555841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of biotechnology products in the global pharmaceutical market: the case of the European community and the United States.
    Hakim Z; Kucukarslan S
    Clin Ther; 1993; 15(2):442-58; discussion 432. PubMed ID: 8519050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restrictions on import of drugs for personal use within the European single market.
    Mäkinen MM; Rautava PT; Forsström JJ
    Eur J Public Health; 2002 Dec; 12(4):244-8. PubMed ID: 12506498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.